of red blood cells and blood haemoglobin concentration. Background. Patients with end-stage renal failure undergoing haemodialysis (HD) are exposed to oxidat-
of our investigation was to examine the role of renal Introduction anaemia in oxidative stress in HD patients.
Methods. MDA and 4-hydroxynonenal (HNE) were
There is increasing evidence that oxygen radicals are measured in three groups of patients undergoing HD:
involved in the progression of renal damage and of group I comprised eight patients with a blood haemouraemic symptoms. The oxidative stress appears to be globin (Hb) <10 g/dl (mean Hb=8.1±1.3 g/dl ), and multifactioral and is thought to be caused only in part group II were eight patients with a Hb >10 g/dl (mean by the impaired kidney function itself [1]. Hb=12.4±1.9 g/dl ); none of these 16 patients had Haemodialysis (HD) is known to be one major cause been treated with human recombinant erythropoietin of oxidative stress due to the activation of polymor-(rHuEpo). Group III comprised 27 patients with a phonuclear neutrophil leukocytes (PMNL) through mean Hb of 10.5±1.6 g/dl after long-term rHuEpo contact of the blood with the dialysis membranes [2] . treatment.
Activated PMNL are able to mediate lipid peroxidation Results. Mean plasma concentrations of both MDA (LPO) in red blood cells (RBC ), which results in and HNE were significantly higher (P<0.0001) in all anaemia in uraemic patients because of the lack of 43 HD patients than in 20 healthy controls (MDA adequate erythropoietin production [3] . In this study, 2.85±0.25 vs 0.37±0.03 mM, HNE 0.32±0.03 vs we were interested in the role of anaemia itself as a 0.10±0.01 mM ). Comparing the three groups, it was secondary cause of oxidative stress. shown that HD patients with a Hb <10 g/dl had Today, the beneficial effect of recombinant human significantly higher plasma levels of LPO products erythropoietin (rHuEpo) for the correction of renal (MDA 3.81±0.86 mM, HNE 0.45±0.07 mM ) than HD anaemia is well established. 
Assays

Subjects and methods
Phosphoric acid, thiobarbituric acid, sodium hydroxide and Subjects BHT were from Sigma, Deisenhofen (Germany). 2,4-Dinitrophenylhydrazine (DNPH ) was from Union In December 1996, all the haemodialysed patients in two Chemique, Brussels (Belgium). Potassium dihydrogenphosdialysis centres who did not belong to one of the following phate, methanol (HPLC-grade) and hydrochloric acid were groups: smokers, patients taking antioxidants (except vitamin from Fluka, Buchs (Switzerland ). Hexane, dichloromethane C in water-soluble vitamin supplements, if the daily amount and thin-layer chromatography (TLC ) plates were from was not more than 60 mg), patients with acute infections, Merck, Darmstadt (Germany). with considerable iron overload and with an acute phase of The detection of HNE was performed according to Poli rheumatological disorders were examined for oxidative stress. et al. [5] including the reaction with DNPH, TLC separation Forty three patients (22 male, 21 female), mean age=62 of DNPH aldehyde adducts and HPLC separation of the years (range 25-88), undergoing HD entered the study. All DNPH-hydroxyalcenals. The Perkin Elmer HPLC system patients were treated with water-soluble vitamins, 29 patients used consisted of a M410 pump system, an LC-95 variable received phosphate binders, 23 sodium bicarbonate, 24 oral wavelength detector and an LCI-100 integrator. A C18 iron supplementation, 25 angiotensin-converting enzyme Nucleosil column (5 mm, 250×40 mm, Machery, Nagel & (ACE ) inhibitors, 36 beta blockers, 33 calcium antagonists Co., Dü ren, Germany) with a 20×4.0 mm pre-column was and 14 digitoxin.
used. Methanol-water (451, v/v) served as eluent for the For an association study, three groups of HD patients isocratic separation. The flow rate was 1 ml/min. were created representing different states of renal anaemia;
MDA was detected according to Wong et al. [6 ] . The group I, eight patients with low Hb <10 g/dl; group II, eight HPLC equipment consisted of a Waters 510 pump, a patients with a higher Hb >10 g/dl; and group III, 27 Shimadzu fluorescence detector RF-530 (525/550 nm) and a patients receiving rHuEpo treatment for >6 months (total Shimadzu integrator C-R6A. The Supelcosil C18 column dosage 7000-12 000 IE/week). None of the patients of group used (5 mm, 150×4 mm, LC-18-S) was from Sulpelco. A I and II had been treated with rHuEpo; they received 50 mM potassium phosphate buffer (pH 6.8) with 40% methtransfusions, vitamin B 12 and folate supplementation, if anol served as eluent with a flow rate of 1 ml/min. necessary. All patients underwent bicarbonate dialysis, and were dialysed for 4-5 h three times weekly. In each group, half the patients were dialysed with cuprophane membranes, Statistics while the others were dialysed with biocompatible mem-
The statistical significance of the data was determined by the branes. The same type of membrane was used for each Mann-Whitney rank sum test and polynomial regression patient 4 months before and during the study. Whatever the analysis. Differences were considered to be statistically signitype of membrane used, we observed no difference in the ficant if P<0.05. result of the present study. Age, gender, characteristics of dialysis and underlying renal disorders of the patients of the studied groups are listed in Table 1 . Twenty healthy subjects (10 male, 10 female), mean age=59 years (range 47-79), Results were chosen as controls.
HNE and MDA concentrations were determined in blood The clinical data of the three different groups of HD plasma. Blood was taken from patients in K-EDTA monov-patients and the healthy controls are shown in Table 2 . group III receiving rHuEpo showed a mean Hb of 10.5 g/dl. There were no significant differences in the supplementation (group III ) showed a HNE plasma concentration of 0.29±0.03 mM, and which was signiother biochemical analyses between the three groups of patients. Compared with healthy controls, serum ficantly lower (P=0.039) than in group I (Hb <10 g/dl, no rHuEpo), but not significantly different creatinine and urea, uric acid and triglycerides were significantly elevated in all three groups of dialysed from group II (Hb >10 g/dl, no rHuEpo). However, the plasma HNE in group III was still significantly patients, whereas serum protein and iron were lower. All other parameter were not significantly different higher than in healthy controls (P<0.0001).
The mean MDA plasma concentration of all 43 from controls.
The mean HNE plasma concentration of all 43 patients was 2.85±0.25 mM, and significantly elevated (P<0.0001) compared with healthy controls patients was 0.32±0.03 mM (mean±SEM ) and significantly higher (P<0.0001) than in healthy controls (0.37±0.03 mM ) (Figure 1 ). HD patients of group I (Hb <10 g/dl, no rHuEpo) had a plasma MDA of (0.10±0.01 mM ). HD patients not treated with rHuEpo and with low Hb <10 g/dl had a mean plasma 3.81±0.86 mM, whereas MDA of group II (Hb >10 g/dl, no rHuEpo) was 2.77±0.58 mM. The differ-HNE value of 0.45±0.07 mM, which was significantly higher (P=0.042) than in patients without rHuEpo ence was not statistically significant (Figure 1 ). The patients of group III (with rHuEpo) had a mean MDA treatment and with Hb >10 g/dl (0.25±0.05 mM ) plasma concentration of 2.50±0.12 mM, which was (Figure 1 ). Those patients with long-term rHuEpo significantly lower (P=0.031) than in group I (Hb <10 g/dl, no rHuEpo), but not significantly different from group II (Hb >10 g/dl, no rHuEpo). Nevertheless, the plasma MDA of group III was still significantly higher than that of healthy controls.
There was an inverse correlation between plasma concentration of HNE and of Hb in patients with and without rHuEpo treatment, and of healthy control subjects ( Figure 2 ). In the polynomial regression analysis for Hb=f [ HNE] , the correlation factor seen for the second order regression was r=0.62, P<0.0001. An inverse correlation was also seen for MDA and Hb (r=0.57, P=0.0035 for the second order regression, data not shown). The same results could be obtained by analysing the correlation between the haematocrit (Hk) of all investigated subjects and the measured aldehydic LPO products (for Hk=f [ HNE] amounts of aldehydic products are formed. Our results uraemia [11] , the accelerated LPO at the low Hb level might be explained by oxidative stress due to the anaemic condition itself.
Anaemic patients show an increased frequency of ventilation at peak exercise because of the limited oxygen transport capacity, implying anaerobic metabolism due to hypoxaemia and ischaemia [12] . This condition may lead to increased blood concentrations of catecholamines, and subsequently to activation of catecholamine-metabolizing enzymes which are wellknown radical generators [13] . In addition, other different important radical sources may be responsible for oxidative stress in anaemic HD patients: final purine degradation via xanthine oxidase in reoxygenation of the temporarily hypoxic tissues [14] , activation of PMNL [15] and partial uncoupling of oxidative phosphorylation [16 ] . On the other hand, since RBC deficiency accompanies a deficit of reduced glutathione products, the blood of uraemic patients loses a major part of its antioxidant power.
Nevertheless, the data should be considered prelimon plasma MDA support those of previous reports. Comparing the three groups, we found a significantly inary at this stage, until the hypothesis is proven by a longitudinal study design. However, since accelerated higher MDA level in group I (Hb <10 g/dl, no rHuEpo) compared with group III (with rHuEpo). LPO was shown to be linked to high rates of oxidatively modified low density lipoproteins (LDL) [18] , which These results might be in contrast to the observations of Cavdar et al. who reported that MDA levels were are reported to be responsible for an increased risk of atherosclerosis and cardiac disease, a significant not affected by treatment with rHuEpo after a time period of 3 months [7] . However, MDA is also a decrease in oxidative stress due to the rejuvenation of the RBC population by rHuEpo may reduce progresswater-soluble LPO product and might be partially excreted via urine under normal conditions [8] or even ive organ damage in ESRF patients undergoing HD. removed by HD, as shown in children by Daschner
